International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Recategorization of Psoriasis Severity

Disease severity criteria can significantly impact a psoriasis patient’s eligibility for treatment. While their disease may profoundly affect their quality of life, the current clinical definition of psoriasis severity is narrow. It does not account for the many potential challenges the disease may cause in a patient’s life.

In 2019, IPC began a project to redefine the criteria used for assessing disease severity that would better guide clinical decision-making to be more meaningful, practical, and better aligned with the actual severity of a patient’s disease. IPC is also working to strengthen psoriasis treatment guidelines and guide future clinical trials of drugs targeting various severities of psoriasis.

Fast Facts

  • Typically, patients must have a PASI of 10 or 12 to be eligible for systemic treatments.
  • Despite this, patients with a PASI or BSA score below ten can experience significant impairment in their quality of life.
  • Reclassification would allow for more specific clinical severity criteria that can guide clinical decision-making to be more practical, meaningful, and better aligned with the severity of a patient’s disease.

IPC Resources

PUBLICATIONS AND RESEARCH

PSORIASIS SEVERITY: COMMONLY USED CLINICAL THRESHOLDS MAY NOT ADEQUATELY CONVEY PATIENT IMPACT

Golbari NM, van der Walt JM, Blauvelt A, Ryan C, van de Kerkhof P, Kimball AB. J Eur Acad Dermatol Venereol. 2020 Sep 25. doi: 10.1111/jdv.16966.

RECATEGORIZATION OF PSORIASIS SEVERITY: DELPHI CONSENSUS FROM THE INTERNATIONAL PSORIASIS COUNCIL

Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, Blauvelt A. Journal of the American Academy of Dermatology (2019), doi: https://doi.org/10.1016/j.jaad.2019.08.026.

VIDEOS

IPC'S Disease Severity Classification: What It Means In The Clinic

Lone Skov, MD, PhD Denmark
September 2021
[10:08 min]

Psoriasis Disease Severity Recategorization: Update

Bruce E. Strober, MD, PhD | United States
April 2021
[11:47 min]

More from the IPC

image of computer with words expert commentary

Commentary: Psoriasis treat to target: defining outcomes in psoriasis

In moderate to severe psoriasis, there has been a long-lasting tradition to define outcome as a relative change from baseline PASI, with the classical PASI 75 being more recently replaced by PASI 90 or 100. However, this concept is dated, mainly due to the impressive development of anti-interleukin therapies and an increasing interest in real-world evidence.

Read More »

Meet IPC Experts

Bruce Strober

Bruce

Strober

,

MD, PhD

Central Connecticut Dermatology

Avon

,

Connecticut

,

United States

Lone

Skov

,

MD, PhD

Herlev and Gentofte Hospital, University of Copenhagen

Hellerup

,

Denmark

Additional Resources

Below are links to trusted resources on disease severity reclassification. 

WEBSITES

In Conversation: A New Method of Classifying Psoriasis Severity from the International Psoriasis Council
In this three-part video series by Novartis, Dr. Bruce Strober and Dr. Andrew Blauvelt discuss the new IPC classification.
It’s Time for a Change: IPC Psoriasis Severity Reclassification (CME)
Listen as IPC Board Member Dr. Bruce Strober and IPC Councilor Dr. Andrew Blauvelt discuss the International Psoriasis Council’s rationale for changing psoriasis severity classification for treatment decisions and clinical trials in this NPF podcast.